NCT07083609 - Treatment Outcomes of Direct Oral Anticoagulants in Cerebral Venous Thrombosis in Vietnam | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 11, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions

Cerebral Venous Thrombosis

Interventions

DRUG

Dabigatran

Dabigatran will be initiated between 5 and 15 days after therapeutic-dose heparin in patients with cerebral venous thrombosis (CVT), based on clinical judgment. It is administered as part of routine clinical care.

DRUG

Rivaroxaban

Rivaroxaban will be initiated between 5 and 15 days after therapeutic-dose heparin in patients with cerebral venous thrombosis (CVT), based on clinical judgment. It is administered as part of routine clinical care.

Trial Locations (1)

100000

RECRUITING

Bach Mai Hospital, Hanoi

All Listed Sponsors

lead

Hieu Trung Dinh

OTHER